Loper Bright Unlikely To Upend DEA Rescheduling Challenges
Having rescheduled certain U.S. Food and Drug Administration-approved products containing cannabis and state-licensed medical cannabis to Schedule III in April, the U.S. Drug Enforcement Administration concluded its administrative hearing on broader cannabis...To view the full article, register now.
Already a subscriber? Click here to view full article